Foster City, California, United States · Est. 1987 · 17,000 employees
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and commercializing medicines in virology, oncology, and inflammation.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 7 drugs with upcoming expirations
Pipeline
By Phase
30 drugs in development
By Therapeutic Area
top 4
R&D Momentum
84/100
Pipeline Velocity
47/100
Trial Completion Rate
76/100
Pipeline Concentration
26/100
Pipeline Freshness
65/100
Strategic Signals
Activity
Last 14 days
A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
FORM 8-K
A Phase 2 Proof-of-Concept Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Active Treatment Extension Period to Assess the Safety and Efficacy of Seladelpar and Cilofexor in Combination for Primary Biliary Cholangitis
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
A Platform, Active-Controlled Study Evaluating the Safety and Efficacy of Long-Acting Oral Regimens in People With HIV-1; Substudy-01: Phase 2, Open-Label, Weekly, Long-Acting, Oral Regimens in Virologically Suppressed People With HIV-1
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-5319 Monotherapy and Combination Therapy in Adults With MTAP-deleted Advanced Solid Tumors
Details
Company Overview
$100.0B
Mkt Cap
$22.1B
Revenue
$5.3B
Cash
Therapeutic Focus
Recent SEC Filings
FORM 8-K
FORM 8-K
GILEAD SCIENCES, INC. (GILD) (CIK 0000882095)
Pipeline
Regulatory
Sovaldi — SOVALDI
Application NDA204671
Sovaldi — SOVALDI
Application NDA212480
Sovaldi — SOVALDI
Application NDA212480
Sovaldi — SOVALDI
Application NDA204671
Sunlenca — SUNLENCA
Application NDA215973
Sunlenca — SUNLENCA
Application NDA215974
Sunlenca — SUNLENCA
Application NDA215974
Sunlenca — SUNLENCA
Application NDA215973
Sunlenca — SUNLENCA
Application NDA215973
Sunlenca — SUNLENCA
Application NDA215974
Tybost — TYBOST
Application NDA203094 (NDA)
Sunlenca — YEZTUGO
Application NDA220018 (NDA)
Sunlenca — YEZTUGO
Application NDA220020 (NDA)
Sunlenca — YEZTUGO
Application NDA220020 (NDA)
Sunlenca — YEZTUGO
Application NDA220018 (NDA)
Sunlenca — YEZTUGO
Application NDA220020 (NDA)
Sunlenca — YEZTUGO
Application NDA220018 (NDA)
FORM 8-K
Accession: 0000882095-26-000037
FORM 8-K
Accession: 0000882095-26-000028
HEPCLUDEX — HEPCLUDEX
Application BLA761468 (BLA)
Sunlenca — SUNLENCA
Application NDA215973
Sunlenca — SUNLENCA
Application NDA215974
GILEAD SCIENCES, INC. (GILD) (CIK 0000882095)
Accession: 000-19731
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)